These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
396 related items for PubMed ID: 18190323
41. The emergence of Stenotrophomonas maltophilia as a significant nosocomial pathogen at the University Hospital of the West Indies. Nicholson AM, Castle D, Akpaka P, Tennant I, Nelson M. West Indian Med J; 2004 Jan; 53(1):17-22. PubMed ID: 15114888 [Abstract] [Full Text] [Related]
43. Honeydew honey as a potent antibacterial agent in eradication of multi-drug resistant Stenotrophomonas maltophilia isolates from cancer patients. Majtan J, Majtanova L, Bohova J, Majtan V. Phytother Res; 2011 Apr; 25(4):584-7. PubMed ID: 20882522 [Abstract] [Full Text] [Related]
44. Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital. Pien CJ, Kuo HY, Chang SW, Chen PR, Yeh HW, Liu CC, Liou ML. J Microbiol Immunol Infect; 2015 Jun; 48(3):291-5. PubMed ID: 24239064 [Abstract] [Full Text] [Related]
45. Association of Stenotrophomonas maltophilia infection with lower airway disease in the horse: a retrospective case series. Winther L, Andersen RM, Baptiste KE, Aalbæk B, Guardabassi L. Vet J; 2010 Dec; 186(3):358-63. PubMed ID: 19758829 [Abstract] [Full Text] [Related]
48. Stenotrophomonas maltophilia bacteremia in burn patients. Tsai WP, Chen CL, Ko WC, Pan SC. Burns; 2006 Mar; 32(2):155-8. PubMed ID: 16448762 [Abstract] [Full Text] [Related]
49. New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Brooke JS. Expert Rev Anti Infect Ther; 2014 Jan; 12(1):1-4. PubMed ID: 24308713 [Abstract] [Full Text] [Related]
50. Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years. Velázquez-Acosta C, Zarco-Márquez S, Jiménez-Andrade MC, Volkow-Fernández P, Cornejo-Juárez P. Support Care Cancer; 2018 Jun; 26(6):1953-1960. PubMed ID: 29307014 [Abstract] [Full Text] [Related]
55. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. Wang WS, Liu CP, Lee CM, Huang FY. J Microbiol Immunol Infect; 2004 Dec; 37(6):359-65. PubMed ID: 15599468 [Abstract] [Full Text] [Related]
57. Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital. Metan G, Hayran M, Hascelik G, Uzun O. Scand J Infect Dis; 2006 Dec; 38(6-7):527-31. PubMed ID: 16798705 [Abstract] [Full Text] [Related]
59. [Study on molecular epidemiology of Stenotrophomonas maltophilia in intensive care units]. Yue W, Huang S, Nie S. Zhonghua Jie He He Hu Xi Za Zhi; 2001 Nov; 24(11):651-4. PubMed ID: 16136901 [Abstract] [Full Text] [Related]
60. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Apisarnthanarak A, Mayfield JL, Garison T, McLendon PM, DiPersio JF, Fraser VJ, Polish LB. Infect Control Hosp Epidemiol; 2003 Apr; 24(4):269-74. PubMed ID: 12725356 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]